Withdrawal of the marketing authorisation application: idebenone (Puldysa)

The company withdrew its application after an ongoing main study, which was expected to provide further evidence for idebenone in Duchenne muscular dystrophy was stopped because it was unable to achieve its objectives.

European Medicines Agency